A 6-month-old infant with Down syndrome is found to have moderate atrioventricular septal defect (AVSD) on echocardiography. He is asymptomatic at rest but has poor weight gain and mild tachypnea on exertion. His parents wish to defer surgery for 2–3 months. Which drug is the first-line choice for preoperative medical management of his left-to-right shunt?

Explanation

## Preoperative Medical Management of Left-to-Right Shunts in Down Syndrome Down syndrome patients with AVSD frequently require preoperative optimization to reduce pulmonary blood flow, improve systemic perfusion, and promote growth before surgical repair. The infant in this vignette has a moderate AVSD with signs of mild heart failure (poor weight gain, exertional tachypnea), making medical management necessary while surgery is deferred. ### First-Line Agent: ACE Inhibitor (Captopril) **Key Point:** Captopril (or other ACE inhibitors such as enalapril) is the **first-line agent** for preoperative management of left-to-right shunts. Its primary mechanism is reduction of systemic vascular resistance (SVR), which decreases the pressure gradient driving blood from left to right, thereby reducing the shunt fraction (Qp:Qs ratio). **High-Yield:** Mechanism in left-to-right shunts: - ↓ SVR → ↓ left-to-right pressure gradient - Reduces pulmonary blood flow (Qp) and pulmonary congestion - Improves systemic perfusion (Qs) - Promotes better weight gain and reduces respiratory symptoms - Does NOT directly affect contractility ### Why Not the Other Options? | Agent | Mechanism | Role in Shunt Management | Verdict | |-------|-----------|--------------------------|---------| | **Captopril** | ↓ SVR via ACE inhibition | ↓ Qp:Qs ratio — addresses root cause | **First-line** | | **Furosemide** | Loop diuretic | Reduces pulmonary edema/congestion — adjunct only; does NOT reduce shunt fraction | Adjunct, not first-line | | **Digoxin** | Inotrope + AV nodal block | Increases LV output → may worsen shunting; used only in overt systolic dysfunction | Avoided in pure shunts | | **Spironolactone** | K⁺-sparing diuretic | Reduces fluid overload — adjunct to furosemide | Adjunct, not first-line | **Clinical Pearl:** Furosemide is commonly co-prescribed alongside ACE inhibitors for symptomatic relief of pulmonary congestion, but it does NOT reduce the shunt itself. The question asks for the **first-line/primary** agent, which is the ACE inhibitor because it uniquely addresses the hemodynamic cause (elevated SVR driving the shunt). Diuretics are supportive adjuncts. This distinction is critical for NEET PG/INI-CET. **Clinical Pearl:** Digoxin increases cardiac contractility, which paradoxically worsens left-to-right shunting by increasing left ventricular output — it should be avoided as monotherapy in pure shunt physiology without systolic dysfunction. **Mnemonic:** **ACES for Shunts** — ACE inhibitors (Captopril, Enalapril) are the **E**ssential first-line; **S**upport with diuretics if needed. **Tip:** The goal in preoperative shunt management is to shift flow from pulmonary (Qp) to systemic (Qs) circulation. Only SVR reduction (via vasodilators like ACE-I) achieves this mechanistically; diuretics and inotropes do not reduce the shunt fraction. [cite: Nelson Textbook of Pediatrics, 21st edition, Chapter 433; Park's Pediatric Cardiology for Practitioners, 6th edition]